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The SYMPLICITY HTN-1
[1]
and HTN-2 studies
[2]
showed that renal denervation (RDN) is feasible as a
novel treatment for resistant hypertension. Despite
great enthusiasm toward this new treatment modality
[3]
,
until now the current evidence rests on only one ran-
domized controlled trial
[2]
. SYMPLICITY HTN-3
[4]
is
a pivotal study started for regulatory purposes in the
United States with the goal to evaluate the efficacy
and safety of RDN in treatment of resistant hyperten-
sion. It is a randomized trial including 535 resistant
hypertensive patients randomized to RDN or control
(sham) in a ratio of 2:1. On 9 January 2014, Medtro-
nic announced that SYMPLICITY HTN-3 failed to
meet its primary endpoint of efficacy (http://newsroom.
medtronic.com/phoenix.zhtml?c5251324&p5irol-
newsArticle&ID51889335&highlight) and that the
final scientific results will be reported at the 63th
Scientific Meeting of the American Cardiology
College, to be held in Washington DC on 29-31
March 2014. In the wake of this announcement, Med-
tronic suspended SYMPLICITY HTN-4 in the United
States, HTN-Japan and HTN-India. Other manufac-
turers halted on-going studies (Covidien) or put their
research programs on hold (St Jude Medical and
Boston Scientific), because of the uncertainty about
what SYMPLICITY HTN-3 will report.
In contrast to the desperation reigning in the com-
pany headquarters, we are convinced that now the time
has come that scientists instead of marketers and
shareholders take the lead in clinical research on
RDN. In our view, there is little uncertainty about what
SYMPLICITY HTN-3 will report at the end of March,
based on the published sample size calculations for the
primary efficacy endpoint based on office systolic
blood pressure
[4]
. These calculations state that ‘‘assum-
ing a true difference between treatment means of
15 mmHg with a 25 mmHg standard deviation of sys-
tolic blood pressure change per group, a sample size
of 316 treated and 158 control patients provides over
95% statistical power to demonstrate a difference of
more than 5 mmHg between treatment groups with a
1-sided a-level of 0.025’’. Assuming a standard devia-
tion of 25 mmHg, the baseline-adjusted between-group
difference in SYMPLICITY HTN-3 should be around
7 mmHg. The confidence interval around 7 mmHg
must pass through zero (no effect) and 5 mmHg,
so that RDN remains inferior to control (sham).
Furthermore, the baseline-adjusted between group
difference in the daytime systolic ambulatory blood
pressure should be approximately 65% of 7 mmHg
(,5 mmHg)[5]. We wonder whether the SYMPLICITY
HTN-3 investigators will report any results on ambula-
tory blood pressure. They stated that if the primary
effectiveness endpoint is met, the major secondary end-
point, change in average 24-h systolic blood pressure by
ambulatory monitoring from baseline to 6 months, will
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be tested
[4]
. This statement implies that if the primary
efficacy endpoint fails to be met, the analysis plan does
not include the ambulatory blood pressure.
While SYMPLICITY HTN-3 was ongoing, thou-
sands of patients underwent RDN in Europe, based
on inconclusive evidence from a single randomized
control led trial
[2]
and on CE label certification. RDN
was therefore deemed safe enough to be deployed on
a large scale in Europe, where this intervention is cur-
rently reimbursed in several countries. From this view
point, the primary endpoint for safety as tested in
SYMPLICITY HTN-3 is completely obsolete. It
encompassed severe events occurring within 1 month
after the procedure. These encompassed death,
decrease of estimated glomerular filtration rate
(eGFR) to below 15 mL/min?m
2
, need for renal repla-
cement therapy, major lesions of the renal artery (per-
foration, dissection, and more than 70% stenosis
occurring up to 6 months after RDN), major cardio-
vascular complications, and hospitalization for hyper-
tensive crisis not related to confirmed nonadherence.
European registries did not report such severe events,
although there were occasional reports of renal arterial
lesions
[6]
. In our view, the primary safety endpoint
should have included changes in renal artery structure,
as picked up by computed tomography or magnetic
resonance angiography and changes in eGFR. As
reviewed by our group
[7]
, one of the SYMPLICITY
reports
[8]
already showed a fall in eGFR of 16 mL/
min /1 .73m
2
. In the long- t e rm fo l low-up of
SYMPLICITY HTN-1
[9]
patients, eGFR declined (P5
0.05) from 83.6 to 74.3 mL/(min?1.73 m
2
). Taking
these observation into account, the SYMPLICITY
HTN-3 investigators should report on eGFR changes.
We presume that eGFR will show some decline in both
treatment groups, for example, as a consequence of
using contrast media, but the decline in eGFR might
be larger in the intervention than control group.
Finally, the SYMPLICITY HTN-3 analysis plan
also calls for subgroup analysis according to race,
diabetes mellitus, sex, age and body mass index to
evaluate the consistency of the results. Before rando-
mization, SYMPLICITY HTN-3 patients were strati-
fied for center and ethnicity. Thus, only the subgroup
analysis by race was predefined. All other subgroup
analysis are therefore post-hoc, vulnerable to chance
findings with large margins of type 1 error. More-
over, because the primary efficacy endpoint was not
met, one wonders what consistency is left over to be
evaluated by subgroup analyses.
In conclusion, in most countries worldwide, the rou-
tine application of RDN in patients with treatment
resistant hypertension is not evidence based but driven
by market forces based on observational studies and
deficient regulation. The first regulatory trial con-
ducted under the guidance of the Food and Drug
Administration in the United States removed the smoke
curtain hiding the large variability in the blood pressure
responses to RDN
[10]
and emphasized that one size will
not fit all, but that only a small niche of carefully
selected patients are likely to benefit from this proce-
dure. New randomized clinical trials designed and led
by scientists should now identify the indications of
RDN in treatment resistant hypertension, so that the
SYMPLICITY debacle and the shortcoming of device
validation process in Europe will not lead to the aban-
donment of a potentially promising technique.
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